Sandoz concludes acquisition of antifungal agent Mycamine from Astellas
Basel: Sandoz has successfully completed the acquisition of worldwide brand rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas.
Through this acquisition of the global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.
Astellas reported Mycamine sales of JPY 14.2 billion (USD 105 million) for the year ending March 31, 2023. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.
Sandoz CEO Richard Saynor said, “This is another sign of our commitment at Sandoz to driving responsible access to critical antimicrobial medicines. We are both investing in our production network and selectively building out our leading portfolio in this field to ensure that we can continue to offer patients around the world the right medicine at the right time.”
Mycamine has a global patient base of well over two million. It is a therapy of choice in hospitals and intensive care units worldwide, a proven prophylactic in hematology and oncology patients, and widely used in organ transplants.
It is indicated for treatment of invasive candidiasis and esophageal candidiasis, which are currently both on the rise with a higher occurrence of associated hospital outbreaks, as well as prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation.
Read also: Sandoz releases positive results from Mylight Phase lll study for biosimilar Aflibercept
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. The company's broad portfolio of medicines covers all major therapeutic areas.
Read also: Sandoz bags USFDA approval for biosimilar Tyruko for relapsing forms of multiple sclerosis
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.